Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil.

摘要: We have recently demonstrated that continuous-infusion (CI) 5-fluororacil (FU) eradicates human colon carcinoma cells made resistant to bolus FU in vitro. In addition, the same experimental system, mechanisms of resistance pulse and CI were found be different. These observations led us test clinical activity a standard regimen (300 mg/m2 per day) cohort 15 patients with advanced measurable colorectal cancer who progression after having failed respond treatment alone (3 patients) combined high-dose 6-S-leucovorin (LV) (12 patients). The median age was 68 years, their Eastern Cooperative Oncology Group performance status (ECOG PS) 1. No myelotoxicity observed. Mild diarrhea, mucositis, vomiting occurred 32%, 26%, 19% patients, respectively, no WHO grade 3 or 4 episodes being noted. all, 6 complained hand-foot syndrome, which severe 2 instances, lasting approximately 1 week. Overall, partial response instances disease stabilization, including minor responses, obtained both had been pretreated first-line FU+LV. Finally, 8 FU. conclusion, these results, clearly progressing treatment, support our finding may overcome by extend this possibility are